Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response.
Ingham Institute of Applied Medical Research, SWS Clinical School, Western Sydney University, Campbelltown, New South Wales, Australia.|Haematology Research Group, SWS Clinical School, University of NSW, Western Sydney University, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia.
N
N
Nikesitch
Haematology Research Group, SWS Clinical School, University of NSW, Western Sydney University, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia.|Department of Haematology, Sydney South West Pathology Service, NSW Health Pathology, Liverpool Hospital, Liverpool, New South Wales, Australia.
C
C
Tao
Anatomical Pathology NSWHP, Liverpool Hospital, Liverpool, New South Wales, Australia.|Cancer Pathology and Cell Biology, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia.
K
K
Lai
Ingham Institute of Applied Medical Research, SWS Clinical School, Western Sydney University, Campbelltown, New South Wales, Australia.|Anatomical Pathology NSWHP, Liverpool Hospital, Liverpool, New South Wales, Australia.|Cancer Pathology and Cell Biology, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia.
M
M
Killingsworth
Haematology Research Group, SWS Clinical School, University of NSW, Western Sydney University, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia.
S
S
Bae
Flow Cytometry Core Facility, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
M
M
Wang
Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.|Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
S
S
Harrison
School of Medicine, SWS Clinical School, University of New South Wales, Kensington, New South Wales, Australia.|University of Queensland Centre for Clinical Research, Herston, Queensland, Australia.|Medical Oncology, SWS Clinical School, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia.
T L
TL
Roberts
Ingham Institute of Applied Medical Research, SWS Clinical School, Western Sydney University, Campbelltown, New South Wales, Australia.|Haematology Research Group, SWS Clinical School, University of NSW, Western Sydney University, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia.|Department of Haematology, Sydney South West Pathology Service, NSW Health Pathology, Liverpool Hospital, Liverpool, New South Wales, Australia.|School of Medicine, SWS Clinical School, University of New South Wales, Kensington, New South Wales, Australia.
S C W
SC
Ling
D051702:Activating Transcription Factor 6 / Q000235:genetics / Q000378:metabolism; D054316:Biomarkers, Pharmacological / Q000032:analysis / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism; D000069286:Bortezomib / Q000009:adverse effects / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D061988:Proteasome Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D056811:Unfolded Protein Response / Q000187:drug effects* / Q000235:genetics
C497111:ATF6 protein, human; D051702:Activating Transcription Factor 6; D054316:Biomarkers, Pharmacological; D014408:Biomarkers, Tumor; D061988:Proteasome Inhibitors; D000069286:Bortezomib